Marchal JA - Search Results

1

Anticancer activity of (1,2,3,5-tetrahydro-4,1-benzoxazepine-3-yl)-pyrimidines and -purines against the MCF-7 cell line: Preliminary cDNA microarray studies.

Díaz-Gavilán M, Gómez-Vidal JA, Rodríguez-Serrano F, Marchal JA, Caba O, Aránega A, Gallo MA, Espinosa A, Campos JM. Díaz-Gavilán M, et al. Among authors: marchal ja. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1457-60. doi: 10.1016/j.bmcl.2007.12.070. Epub 2008 Jan 1. Bioorg Med Chem Lett. 2008. PMID: 18194866

2

Differentiation in the RD rhabdomyosarcoma cell line after electroporation.

Marchal JA, Hernández MJ, Fernández JE, Prados JC, Melguizo C, Aránega A. Marchal JA, et al. Eur J Cell Biol. 1995 May;67(1):94-8. Eur J Cell Biol. 1995. PMID: 7641735 No abstract available.

3

Production and characterization of a new monoclonal antibody, GR-ICOR-2, recognizing sarcomeric actin: analysis of the expression in the developing chick heart.

Fernández JE, Melguizo C, Prados J, Marchal JA, Alvarez L, Aránega A. Fernández JE, et al. Among authors: marchal ja. Histol Histopathol. 1994 Oct;9(4):765-71. Histol Histopathol. 1994. PMID: 7894148

4

Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD.

Melguizo C, Prados J, Marchal JA, Aránega AE, Alvarez L, Aránega A. Melguizo C, et al. Among authors: marchal ja. Pathol Res Pract. 1996 Feb;192(2):188-94. doi: 10.1016/S0344-0338(96)80219-6. Pathol Res Pract. 1996. PMID: 8692721

5

Low sample volume causes differentiation in human rhabdomyosarcoma cell line RD subjected to electroporation.

Aránega A, Marchal JA, Melguizo C, Prados J, Aránega AE, Vélez C, Fernández JE, Arena N, Alvarez L. Aránega A, et al. Among authors: marchal ja. Cell Mol Biol (Noisy-le-grand). 1996 Dec;42(8):1219-27. Cell Mol Biol (Noisy-le-grand). 1996. PMID: 8997525

6

Actinomycin D treatment leads to differentiation and inhibits proliferation in rhabdomyosarcoma cells.

Marchal JA, Prados J, Melguizo C, Fernández JE, Vélez C, Alvarez L, Aránega A. Marchal JA, et al. J Lab Clin Med. 1997 Jul;130(1):42-50. doi: 10.1016/s0022-2143(97)90057-3. J Lab Clin Med. 1997. PMID: 9242365

7

Diheterocyclanes as synthons for the preparation of novel series of nucleoside and acyclonucleoside analogues.

Campos J, Gómez JA, Trujillo MA, Gallo MA, Espinosa A, Marchal JA, Aránega A. Campos J, et al. Among authors: marchal ja. Farmaco. 1997 May;52(5):263-9. Farmaco. 1997. PMID: 9273996

8

Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D.

Prados J, Melguizo C, Marchal JA, Vélez C, Alvarez L, Aránega A. Prados J, et al. Among authors: marchal ja. Int J Cancer. 1998 Jan 30;75(3):379-83. doi: 10.1002/(sici)1097-0215(19980130)75:3<379::aid-ijc9>3.0.co;2-#. Int J Cancer. 1998. PMID: 9455797

9

Optimization of the tyrosinase mRNA probe to detect circulating melanocytes with reverse transcription and polymerase chain reaction.

Carrillo E, Marchal JA, Prados J, Melguizo C, Vélez C, Arena N, Alvarez L, Serrano S, Aránega A. Carrillo E, et al. Among authors: marchal ja. Cell Mol Biol (Noisy-le-grand). 1998 Dec;44(8):1247-52. Cell Mol Biol (Noisy-le-grand). 1998. PMID: 9874512

10

GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells.

Marchal JA, Prados J, Melguizo C, Gómez JA, Campos J, Gallo MA, Espinosa A, Arena N, Aránega A. Marchal JA, et al. Br J Cancer. 1999 Feb;79(5-6):807-13. doi: 10.1038/sj.bjc.6690129. Br J Cancer. 1999. PMID: 10070873 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters